Investment Rating - The report upgrades Sanhua's rating to Overweight (OW) and Xusheng's rating to Equal-weight (EW) [3][5][27] Core Insights - The humanoid robot market is seen as the third wave of growth for automotive parts suppliers, following the electric vehicle and smart vehicle trends [3][22] - The report emphasizes the importance of companies with order visibility and business synergies in the early stages of the humanoid robot industry [3][22] - The potential global market for humanoid robots is estimated to reach USD 5 trillion by 2050, with USD 800 billion coming from China [23][24] Summary by Sections Investment Ratings Overview - Sanhua's new rating is Overweight with a target price of RMB 30, up from RMB 29, due to expected strong revenue in 2025 and long-term growth potential in the global electric vehicle market [5][28] - Xusheng's rating is upgraded to Equal-weight with a target price of RMB 12, reflecting anticipated revenue recovery with the launch of new electric models [5][28] - Tuopu maintains an Overweight rating but has a reduced target price of RMB 63, down from RMB 72, due to lower-than-expected shipments to major electric vehicle clients [5][28] Industry Opportunities - Automotive companies are leveraging their expertise in the automotive sector to enter the humanoid robot market, with a focus on integrating autonomous driving technologies [4][23] - The report identifies key players in the humanoid robot supply chain, highlighting the advantages of first-tier suppliers like Sanhua and Tuopu over second-tier component manufacturers [4][26] - The automotive supply chain is expected to capture 47-60% of the cost share in humanoid robots, driven by their expertise in large-scale manufacturing and mechanical structures [22][24] SWOT Analysis - Strengths include know-how in autonomous driving algorithms and existing sales networks, while weaknesses involve slower decision-making processes compared to startups [14] - Opportunities are significant, with the potential for global expansion for parts suppliers, while threats include geopolitical tensions affecting collaboration [14]

Investment Rating - Industry view is rated as In-Line [9] Core Insights - Property sales and home prices are expected to continue declining in the third quarter due to high secondary inventory and weakening resident sentiment [1] - Quality state-owned enterprises (SOEs) with good visibility are recommended for investment, with CR Land identified as a top pick [1][2] Monthly Property Sales - Home sales in 65 cities saw a year-on-year decrease of 11% in primary sales volume and a 5% decrease in secondary sales volume [3] - Year-to-date growth for primary sales is now at 0.1% and 13% for secondary sales as of May 2025 [3] Property Prices - Primary home prices in 70 cities dropped by 4.1% year-on-year and 0.2% month-on-month, while secondary home prices fell by 6.3% year-on-year and 0.5% month-on-month [4] - In top-10 cities, secondary prices decreased by 5.4% year-on-year, and in top-100 cities, they fell by 7.2% year-on-year [4] Secondary Market - Listing volume for secondary properties increased, with new listings up by 6% year-on-year but down 11% month-on-month [5] - Client visits to properties increased by 20% year-on-year and 3% month-on-month [5] Inventory - Primary inventory levels in tracked cities remained stable at 23.4 months, with tier 1 cities decreasing slightly to 14.2 months [6] Land Market - Land sales in 300 cities decreased by 13.8% year-on-year in gross floor area (GFA) but increased by 17.8% in value [7] - The year-to-date decline in land sales is now at 6.4% in GFA [7]

Investment Rating - The report upgrades Sanhua to "Overweight" (OW) and Xusheng to "Equal Weight" (EW) based on their potential in the humanoid market and expected revenue recovery [6][27]. Core Insights - Humanoid robots are anticipated to create a third wave of growth for auto parts suppliers, following the previous waves driven by vehicle electrification and smartization [2][36]. - The report emphasizes the importance of companies with order visibility or business synergy in the emerging humanoid market [1][4]. Summary by Sections Humanoid Market Opportunity - The humanoid industry is still in its infancy, presenting significant growth potential for auto parts suppliers, particularly tier-1 suppliers like Sanhua and Tuopu, who are better positioned to capture this growth [5][26]. - The global humanoid market is estimated to reach US$5 trillion by 2050, with a notable US$0.8 trillion market in China [23][24]. Advantages for Auto Companies - Auto OEMs can leverage their expertise in autonomous driving and large-scale manufacturing to develop humanoid robots, which can initially operate in auto factories [4][21]. - Chinese humanoid parts suppliers have a cost advantage over their global counterparts, although their success may depend on geopolitical factors such as US import tariffs [4][24]. Company Ratings and Price Targets - Sanhua's price target is upgraded to RMB 30 from RMB 29, reflecting stronger revenue expectations and the potential for humanoid actuator module supply [30]. - Xusheng's price target is adjusted to RMB 12 from RMB 13, with expectations of modest revenue recovery amid competitive pressures [31]. - Tuopu remains rated OW, but its price target is reduced to RMB 63 from RMB 72 due to weaker shipments to overseas customers [32]. Historical Context and Growth Waves - The report outlines two previous growth waves in the auto industry: electrification (2021-22) and smartization (since 2022), which have significantly impacted the revenue and valuation of auto parts suppliers [36][42]. - The electrification wave saw China's NEV penetration rate increase from 15% in 2020 to 36% in 2022, while the smartization wave has driven up the adoption of advanced driving technologies [37][42].

J P M O R G A N Global Markets Strategy 18 June 2025 This material is neither intended to be distributed to Mainland China investors nor to provide securities investment consultancy services within the territory of Mainland China. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan. Flows & Liquidity Thoughts on the dollar-equity correlation Cross Asset Fund Flow Monitor Current level shows the latest percentile of weekly flows; Min is d ...

Investment Rating - The report rates the China Healthcare industry as Attractive [4]. Core Insights - The National Health Commission (NHC) has published guidelines for the "2025 Tertiary Hospital Accreditation Standards," focusing on enhancing hospital accreditation processes and supporting primary healthcare institutions [2]. - WuXi Biologics has begun construction of a microbial manufacturing facility in Chengdu, featuring a 15,000L fermentation tank with an annual production capacity of 80-110 drug substance batches and potential expansion to 60,000L [2]. - The National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation for Sac-TMT in combination with tagitanlimab for treating non-squamous non-small cell lung cancer [2]. Summary by Sections Regulatory Developments - The NHC's guidelines aim to improve tertiary hospital capabilities, emphasizing critical medical services and innovation [2]. Company Updates - WuXi Biologics' new facility will be the first in China to have a two-chamber lyophilization line, capable of producing over 10 million bottles of drug product annually [2]. - Other companies like Kelun Bio and Huadong Medicine have received NMPA approvals for clinical trials, indicating ongoing innovation in the sector [8]. Market Trends - The report highlights a decline in net fund flows in the healthcare sector, with a net outflow of RMB 2,476,000 in the past week, reflecting a cautious investor sentiment [15][16].

Investment Rating - The report maintains a selective and defensive bias, preferring gas over oil in the North American Energy sector [5][7]. Core Insights - WTI oil prices have increased approximately 20% in June due to geopolitical risks and a tight crude market, but prices are expected to trend lower in the second half of 2025 unless there are significant supply disruptions [4][28]. - The report emphasizes a preference for US natural gas over oil, with EQT identified as a top pick in the Exploration & Production (E&P) sector [7][9]. - Refining margins have improved significantly, with a 30% quarter-over-quarter increase, leading to 2Q EBITDA estimates that are about 10% above consensus [7][10]. Summary by Sector US Majors - The US Majors provide exposure to higher oil prices while maintaining resilience if prices decline, supported by strong balance sheets and integrated operations [9]. - Estimated free cash flow (FCF) yields for XOM and CVX are projected at 7% and 8% respectively at a WTI price of $65 [9]. US Exploration & Production (E&P) - The report retains a defensive stance, favoring US gas over oil, with a median FCF yield forecast of 9% for gas at $4.40 Henry Hub [9]. - Positive rate of change is a focus for oil producers, with OW-rated DVN and PR highlighted [9]. Canadian Producers - Large-cap Canadian oil sands operators are expected to perform in line with US peers, with a forecasted median shareholder return yield of 9% at $65 WTI [9]. Energy Services & Equipment (ESE) - Preference is given to international and offshore upstream exposure, gas over oil, and non-upstream exposure, with BKR and SLB identified as key stocks [9]. Refining & Marketing - Refining margins are expected to benefit from summer demand, with key stock picks including VLO and DINO [10]. Midstream Energy Infrastructure - Midstream remains misvalued, with a recommendation to wait for a better entry point before deploying new capital [13]. High Yield Energy (Credit) - The sector is currently underperforming, with a recommendation to focus on gas-levered and balanced commodity exposure over oil-levered credits [13].

Investment Rating - The industry investment rating is Attractive [6]. Core Insights - A new study in Italy indicates that Surgical Aortic Valve Replacement (SAVR) may have better mortality outcomes compared to Transcatheter Aortic Valve Replacement (TAVR) in younger patients with intermediate surgical risk, showing all-cause mortality rates of approximately 47.2% for TAVR versus 24.6% for SAVR in Lombardy, and 44.1% versus 18.1% in Puglia [1][4]. - The study involved around 7,000 patients and suggests that recent advancements in SAVR techniques may contribute to these findings, contrasting with previous sponsor studies [1]. - In the kidney transplant sector, data from the European Renal Association suggests that less stringent donor criteria do not necessarily correlate with improved survival outcomes, particularly as recipient age increases [4]. - The demand for kidney transplants is rising, with over 60,000 adults currently on the waitlist, which may lead to broader acceptance criteria by transplant centers [4]. - SS Innovations International performed the first fully-robotic cardiac surgery in the Americas, indicating a growing trend in robotic-assisted surgeries [9]. - GE HealthCare Technologies' Flyrcado software has been shown to enhance throughput for cardiac imaging, presenting a significant market opportunity estimated at around $500 million [10]. Summary by Sections Surgical Aortic Valve Replacement (SAVR) vs. Transcatheter Aortic Valve Replacement (TAVR) - The study highlights a significant difference in mortality rates favoring SAVR over TAVR in younger patients [1][4]. - The findings challenge previous clinical trial results and suggest that advancements in surgical techniques may be influencing outcomes [1]. Kidney Transplantation - The European Renal Association's findings indicate that broader donor criteria may not lead to better survival rates, especially in older recipients [4]. - The increasing number of patients on the kidney waitlist is pushing centers to reconsider donor acceptance criteria [4]. Robotic Surgery and Imaging Technology - The first fully-robotic cardiac surgery in the Americas marks a milestone for robotic surgical technology [9]. - The introduction of Flyrcado software by GE HealthCare Technologies is expected to significantly improve cardiac imaging efficiency, with a notable market potential [10].

Investment Rating - The report does not explicitly provide an investment rating for the industry or specific companies. Core Insights - A-share investor sentiment remains flat amid lukewarm macro conditions and geopolitical instability, with the weighted MSASI at 66% and simple MSASI at 53% as of June 18, 2025 [2][7] - The PBOC announced measures to open up China's financial markets, including a digital RMB international operating center and pilot programs for offshore trade, which may benefit financial companies [5] - Real GDP is tracking at 4.8% YoY, with expectations of deceleration to below 4.5% in the second half of the year due to weak domestic demand and the payback of export front-loading [4] Summary by Sections A-Share Market Sentiment - A-share investor sentiment indicators remained flat, with average daily turnover for ChiNext, Equity Futures, and Northbound rising by 3%, 13%, and 9% respectively, while A-shares saw a 1% decline [2] - Southbound net inflows reached US$2.4 billion from June 12-18, with year-to-date inflows at US$88.5 billion [3] Economic Outlook - The report anticipates a deceleration in real GDP growth to below 4.5% in the second half of 2025, influenced by weak domestic demand and the expiration of a tariff truce [4] - Retail sales showed improvement due to trade-in subsidies, but overall consumer goods sales remain subdued [4] Financial Market Developments - The PBOC's measures aim to enhance overseas development and open up financial markets, indicating a shift in focus from risk control to development [5] - The report highlights potential volatility in the market, particularly for high beta stocks, as geopolitical uncertainties persist [15]

Investment Rating - The report assigns an "Equal-weight" rating to Marvell Technology Group Ltd, with an industry view classified as "Attractive" [5][33]. Core Insights - Marvell is positioned to benefit from a rapidly growing total addressable market (TAM) in AI, targeting approximately $19 billion in AI data center revenue by CY2028, with $11 billion expected from XPU compute/attach [3][8]. - The company has increased its data center TAM to $94 billion, reflecting a 26% growth from the previous year, and anticipates that Custom XPU and "Custom XPU attach" will reach $55.4 billion by CY2025 [3][8]. - Marvell's custom silicon pipeline includes over 50 projects, which could yield a potential lifetime revenue of $75 billion, indicating significant growth opportunities in the AI sector [10][18]. Summary by Sections Financial Projections - Expected EPS for fiscal years are projected as follows: $1.57 for FY2025, $2.76 for FY2026, $3.15 for FY2027, and $3.44 for FY2028 [5]. - The company anticipates a gross margin of 60.2% in 2025, decreasing slightly to 57.7% by 2028 [37]. Market Position and Strategy - Marvell aims for a 20% market share in the new data center TAM, with over 50% of data center revenue expected to come from custom solutions [8][10]. - The company has announced two new XPU compute projects and four XPU attach sockets for emerging hyperscaler customers, enhancing its competitive position in the market [10][18]. Customer Engagement and Growth Potential - Marvell has secured 18 custom compute sockets with U.S. and emerging hyperscalers, indicating strong demand for its custom silicon solutions [10][27]. - The company is optimistic about its growth potential in optical technologies, which are expected to provide higher margins compared to custom silicon [18][33]. Risk and Valuation Considerations - The report suggests that while Marvell has significant AI opportunities, the success rate of custom silicon projects has been mixed, leading to a more conservative outlook on some aspects of its growth [12][20]. - The price target for Marvell is set at $73.00, reflecting a valuation that considers both growth potential and current market conditions [5][28].

Investment Rating - The industry investment rating is Attractive [6]. Core Insights - Taiwan has added Huawei and SMIC to its export control list, requiring government permission for Taiwanese firms to conduct business with these companies, marking a significant regulatory shift [3][8]. - The report highlights Disco and Advantest as key players in the back-end semiconductor production equipment (SPE) market, which is less exposed to regulatory risks compared to front-end processes [8][10]. - There is an ongoing trend in China to promote domestic production of SPE, particularly for front-end processes, although the report suggests that China will eventually achieve self-sufficiency in high-performance components [4][9]. Summary by Sections Export Controls and Market Dynamics - Taiwan's Bureau of Foreign Trade updated its entity list, adding major Chinese firms, which may lead to similar actions by other US allies [3]. - The report emphasizes the need to monitor potential export restrictions from US allies on Japanese SPE [8]. Back-End Equipment Focus - The back-end process equipment is simpler and has seen successful localization in China, reducing the impact of export restrictions [9]. - Disco and Advantest are highlighted for their strong market positions and engineering capabilities, which allow them to maintain high market shares in China [10]. Company Ratings and Price Targets - Advantest is rated Overweight with a target price of ¥10,300 based on expected earnings growth [17]. - Disco is also rated Overweight with a target P/E of 25.1x, reflecting its strong growth potential [14].